Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04989218 | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)(ICC) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 |
| clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 10 | jianming xuOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | terminated | Phase 1 / Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | terminated | Phase 1 / Phase 2 | 89 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 21 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 3 | Jul 11, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX(SLC-0111-17-01) | terminated | Phase 1 / Phase 2 | 6 | British Columbia Cancer AgencyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 8 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma(DEDUCTIVE) | terminated | Phase 1 / Phase 2 | 27 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) | terminated | Phase 1 | 9 | Codiak BioSciencesINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | terminated | Phase 1 | 4 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma | terminated | Phase 1 | 10 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases(AntiCEA_CART) | terminated | Phase 1 | 2 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | terminated | Phase 1 | 12 | Danielle Kim TurgeonOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | terminated | Phase 1 / Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | terminated | Phase 1 | 2 | Eureka Therapeutics Inc.INDUSTRY | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma | terminated | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Kathy MillerOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 7 | SignalRX Pharmaceuticals, Inc.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma(DESPARTH) | terminated | Phase 1 | 2 | University Hospital, GhentOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | terminated | Phase 1 | 15 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 5, 2024source: clinicaltrials